Background: Abiraterone acetate (AA) is a potent, selective androgen (CYP17) biosynthesis inhibitor, which showed to improve overall survival in mCRPC pts progressing after docetaxel. Few data are available concerning the clinical outcome of AA treatment in mCRPC in terms of the duration of prior androgen deprivation therapy (ADT). In this retrospective analysis we assessed the PFS and OS in patients affected with mCRPC according to the duration of ADT

Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. a “real life” retrospective analysis of progression-free (PFS) and overall survival (OS) according to duration of androgen deprivation therapy / Maria Agnese Fabbri, ; Marchetti, Paolo; Cortesi, Enrico; Santini, Daniele; Teresa, Gamucci; Francesco, Angelini; Isabella, Sperduti; Flavia, Longo; Arianna, Pellegrino; Milano, Annalisa; Silvia, Quadrini; Mancini, Ml; Francesca, Primi; Fabrizio, Nelli; Raffaele, Ratta; Enzo, Ruggeri. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - ELETTRONICO. - 34:Suppl.2(2016). ((Intervento presentato al convegno 2016 ASCO Genitourinary Cancers Symposium tenutosi a San Francisco nel January 7-9 [10.1200/jco.2016.34.2].

Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. a “real life” retrospective analysis of progression-free (PFS) and overall survival (OS) according to duration of androgen deprivation therapy

MARCHETTI, PAOLO;Enrico Cortesi;Daniele Santini;MILANO, ANNALISA;
2016

Abstract

Background: Abiraterone acetate (AA) is a potent, selective androgen (CYP17) biosynthesis inhibitor, which showed to improve overall survival in mCRPC pts progressing after docetaxel. Few data are available concerning the clinical outcome of AA treatment in mCRPC in terms of the duration of prior androgen deprivation therapy (ADT). In this retrospective analysis we assessed the PFS and OS in patients affected with mCRPC according to the duration of ADT
2016 ASCO Genitourinary Cancers Symposium
.
04 Pubblicazione in atti di convegno::04c Atto di convegno in rivista
Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. a “real life” retrospective analysis of progression-free (PFS) and overall survival (OS) according to duration of androgen deprivation therapy / Maria Agnese Fabbri, ; Marchetti, Paolo; Cortesi, Enrico; Santini, Daniele; Teresa, Gamucci; Francesco, Angelini; Isabella, Sperduti; Flavia, Longo; Arianna, Pellegrino; Milano, Annalisa; Silvia, Quadrini; Mancini, Ml; Francesca, Primi; Fabrizio, Nelli; Raffaele, Ratta; Enzo, Ruggeri. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - ELETTRONICO. - 34:Suppl.2(2016). ((Intervento presentato al convegno 2016 ASCO Genitourinary Cancers Symposium tenutosi a San Francisco nel January 7-9 [10.1200/jco.2016.34.2].
File allegati a questo prodotto
File Dimensione Formato  
Fabbri_Abiraterone_2016.pdf

accesso aperto

Tipologia: Documento in Pre-print (manoscritto inviato all'editore, precedente alla peer review)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 847.82 kB
Formato Adobe PDF
847.82 kB Adobe PDF Visualizza/Apri PDF
Fabbri_copertina_Abiraterone_2016.pdf

accesso aperto

Tipologia: Altro materiale allegato
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 190.18 kB
Formato Adobe PDF
190.18 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/862086
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 1
social impact